Safety Concerns Hit Neurocrine's Vykat Following Reports of Deaths and Adverse Events

Key Facts

1Reports emerged of seven deaths and 100 serious adverse events linked to Neurocrine Biosciences’ Prader-Willi syndrome drug, Vykat.

2Aardvark Therapeutics terminated its Phase 3 trial for ARD-101 for the same condition due to cardiac safety signals.

In a move reflecting heightened risks within the biotech sector, Neurocrine Biosciences is facing scrutiny following reports linking its drug Vykat to serious health incidents. According to reports, seven deaths and 100 serious adverse events have been recorded in connection with the drug, which is used to treat Prader-Willi syndrome. These developments have prompted clinicians and advocacy groups to investigate causality and the drug's safety profile.

This news arrives as the Prader-Willi syndrome treatment landscape faces broader challenges, with competitor Aardvark Therapeutics terminating its Phase 3 trial for ARD-101. The termination was driven by cardiac safety signals, underscoring the clinical difficulties inherent in treating this condition. Per market dynamics, these safety concerns could impact the commercial trajectory and regulatory standing of Neurocrine's specialized offerings.

With updated price data for the instrument unavailable at the close of August 12, 2026, market attention shifts toward potential regulatory responses. Investors are also looking ahead to broader US economic catalysts, such as the Initial Jobless Claims scheduled for August 6, which may influence overall market sentiment and risk appetite for healthcare equities.

Sources:

BioSpace